Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00136084
Completed
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/02/2012
Locations: Cook Children's Medical Center, Fort Worth, Texas +2 locations
Conditions: Leukemia, Myelocytic, Acute
Register for Updates
Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage
NCT00890656
Completed
The goal of this clinical research study is to learn if a special combination of chemotherapy drugs called "augmented hyper-CVAD chemotherapy" given over 6 to 8 months followed by monthly maintenance chemotherapy for one year can help to control acute lymphoblastic leukemia or lymphoblastic lymphoma. The safety of this therapy will also be studied.
Gender:
ALL
Ages:
All
Trial Updated:
02/17/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer
NCT00507858
Completed
Primary Objective: * To determine the maximum tolerated doses (MTDs) of pemetrexed when given with dexamethasone. (Please note: One of the three treatment groups will not receive dexamethasone) Secondary Objectives: * To assess dose limiting toxicity (DLT), which is defined as grade 4 neutropenia \> 7 days duration, neutropenic fever, grade 4 thrombocytopenia, or any grade 3 or 4 non-hematologic toxicity excluding nausea/vomiting and excluding grade 3 transaminase toxicity. * To determine obj... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/22/2011
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Head and Neck Cancer
Register for Updates
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: University of Texas Southwestern Medical Center, Dallas, Texas +1 locations
Conditions: Multiple Myeloma
Register for Updates
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
NCT00576251
Completed
The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis
Gender:
ALL
Ages:
2 years and above
Trial Updated:
02/23/2010
Locations: Houston, Houston, Texas
Conditions: Ocular Inflammation Associated With Blepharaconjunctivitis
Register for Updates